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ABSTRACT 
A novel prophylactic regimen is demanded for preventing bladder cancer recurrence, because of the high side-effect 
tolls of conventional adjuvant Bacillus Calmette-Guérin (BCG) immunotherapy, in addition to its only moderate effi- 
cacy. In vitro and animal studies have demonstrated the anti-cancer properties of a medicinal mushroom called Gano- 
derma lucidum (GL). In this study, a pre-malignant human uroepithelial cells (HUC-PC) model was utilized to compare 
the effectiveness between ethanol extract of GL (GLe) and BCG on interleukin-6 (IL-6) secretion and lactate dehydro- 
genase (LDH) cytotoxicity. Additionally, parameters relevant to the BCG efficacy and safety, including free soluble 
fibronectin (FN) and cell-surface glycosaminoglycans (GAGs) levels were tested, following the exposure of GLe to the 
cells. GLe at 100 μg/ml and BCG at 4.8 × 107 CFU were shown to induce equivalent levels of IL-6, suggesting the po- 
tential synergism, while the tested concentrations of GLe were non-cytotoxic. During the initial four hours of GLe ex- 
posure, the free FN concentrations in harvested media were significantly reduced that might facilitate the binding of 
BCG for uroepithelial internalization to enhance BCG efficacy. Furthermore, the cell membrane-bound GAGs levels of 
HUC-PC cells were significant increased in response to GLe to suggest cellular protection from BCG infection. In 
summary, current findings suggest the potential additive synergism of GLe with the BCG efficacy, as well as its protec- 
tive effects, and thus reducing the BCG toxicity. 
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1. Introduction 
Ganoderma lucidum (GL), a popular ancient medicinal 
mushroom ranked as a superior tonic in traditional Chi- 
nese medicine, is commonly used for health promotion 
and longevity. Nowadays, the mushroom is being used 
by many cancer patients because of its perceived health 
benefits including immunomodulating properties and 
antitumorigenicity. In the recent years, our research team 
and collaborators have focused on bladder cancer, and 
reported a range of in vitro chemopreventive activities 
for GL. It was demonstrated that remarkable growth in- 
hibitory effects via G2/M phase cell cycle arrest [1] and 
apoptosis [2] were exhibited by a defined ethanol extract 
of GL (GLe) on the pre-malignant human uroepithelial 
cell line (HUC-PC). The GLe-treated HUC-PC cells 
were also characterized to have significant oxidative DNA 
damage [3] and secretion of several cytokines including 
IL-2, IL-6 and IL-8, [4] altogether suggesting the proin- 
flammatory mechanism for adverse cell eradication. Fur- 
thermore, GLe was found to suppress the migration and 
telomerase activity that induced by a bladder cancer-re- 
levant carcinogen 4-aminobiphenyl [1,2]. 
The recurrence rate of superficial transitional cell car- 
cinoma (TCC) of bladder remains exceptionally high 
even with the effective transurethral resection (TUR) 
technique [5]. Refers to the “field cancerization hypothe- 
sis” and “seeding theory”, residual cells at treated and adja- 
cent sites are highly susceptible for mutagenic attacks *Corresponding author. 
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and can potentially develop into tumors again, and hence 
powerful chemopreventive agents are demanded for pro- 
phylaxis [6]. Bacillus Calmette-Guérin (BCG), is cur- 
rently the most effective prophylactic agent available and, 
when introduced intravesically, it triggers a local inflam- 
matory response inside the urinary bladder [7,8]. In re- 
sponse to BCG, host leukocytes infiltrate into the urothe- 
lial wall and are responsible for most of the urinary cyto- 
kine secretion [9,10]. Evidence has also indicated that in 
situ lymphocytes are able to eradicate BCG-internaliz- 
ing tumor cells through specific cell lysis against my- 
cobacterial antigens [11]. However, only certain cyto- 
kines, including IL-2, IL-6 and TNF-α, are detectable in 
a patient’s urine within the first 24 hours upon BCG in- 
stillation [12]. Particularly, the two pro-inflammatory cy- 
tokines, IL-6 and TNF-α, could also be secreted from 
various human bladder cancer cell lines [13-15]. Interest- 
ingly, well-differentiated bladder tumor cells that are in- 
capable of internalizing BCG were also unable to up- 
regulate IL-6 expression [16]. In contrast, normal urothe- 
lial cells and poorly differentiated TCC cells were able to 
internalize BCG and produce IL-6 [11,16]. Therefore, 
IL-6 cytokine was considered as an indicative marker for 
BCG internalization [17]. Given that binding of BCG to 
the urothelial surface is a pre-requisite for successful in- 
ternalization [17], the urothelium and mycobacterium are 
linked through fibronectin (FN) opsonization [18-20]. For- 
mation of FN bridges might facilitate the process of BCG 
internalization [17-19]. Such linkage induces the expres- 
sion of the IL-6 gene through NF-κB and AP-1 signal 
transducers in bladder tumor cells [21]. However, excess 
free FN was reported to be competitive with each other 
for the limited binding sites on urothelium and BCG sur- 
face, and thus impairing the internalization of BCG and 
its subsequent responses [22]. Besides its efficacy, BCG 
instillation also has high side-effect tolls of up to 90% of 
the patients develop cystitis and haematuria [8]. Patients 
receiving BCG treatment are taking the risk of systemic 
mycobacterial infection that could be lethal, although it is 
rare [23]. In fact, direct adhesion is not required for the 
process of BCG internalization, where a close-docking 
distance (70 - 100A) is set by the repellent force between 
BCG and urothelium [24,25]. The luminal wall of the 
bladder is protected by the mucosal lining that is covered 
with negatively charged glycosaminoglycans (GAGs), 
which keeping away the bacteria and toxins from certain 
distance of the anionic urothelial mucosa.[17] Thus, free 
FN concentration and cell surface-bound GAGs are two 
relevant biomarkers for BCG binding efficiency as well 
as potential toxicity. 
In the present study, the HUC-PC cell model is con- 
tinuously being utilized, firstly to compare between the 
effectiveness of GLe and BCG on the cytotoxicity and 
IL-6 secretion. IL-6 has been suggested to be responsible for 
the cytotoxicity of BCG on several TCC cell lines [26,27]. 
Whether BCG and GLe would both be cytotoxic to 
HUC-PC was determined using the LDH cytotoxicity 
assay, if they are capable of inducing IL-6 secretion. 
Secondly, the effects of GLe on extracellular FN and cell 
surface GAGs are explored. These findings will aid in 
elucidating whether GLe is a possible candidate to sup- 
plement or even replace the BCG immunotherapy. 
2. Materials and Methods 
2.1. Preparation of GLe and BCG 
The active ingredients of RishiMax GLPTM G. lucidum 
(Pharmanex, Hong Kong) were commercially standard- 
ized to 13.5% polysaccharides and 6% triterpenes. Pow- 
dered G. lucidum from capsules was re-extracted as pre- 
viously described [3,4]. GLe was dissolved freshly in 
absolute ethanol (0.1% v/v) and diluted with culture me- 
dium to make a 1000 μg/ml stock solution. The whole 
vial (dry weight 81 mg) of live attenuated BCG (IM- 
MUCYST®, Aventi, Toronto, Ontario, Canada) was re- 
constituted with 3 ml of the accompanying diluents to 
make a suspension containing a minimal dosage of 6.6 × 
108 colony forming units (CFU). A 4.8 × 107 CFU BCG 
stock solution was prepared with culture medium. For 
assays, working assay media were prepared by further 
diluting the stock solutions of GLe and BCG into the 
concentrations of test ranges. Solvent media containing 
the maximal amount of corresponding solvent, i.e. 0.1% 
v/v ethanol for GLe and 33% v/v diluents for BCG, were 
used as controls. Furthermore, GLe and BCG were 
checked using Limulus Amebocyte Lysate (LAL) end- 
point chromogenic kit assay (CAPE CO, E. Falmouth, 
MA, USA) for lipopolysaccharides (LPS) contamination. 
GlucashieldTM buffer (CAPE COD) was used to recon- 
stitute pyrochrome to inhibit possible (1,3)-β-D-glucan 
presented in samples, and thus avoiding potential inter- 
ference in the assay. Aseptic techniques were strictly ap- 
plied throughout the procedures. 
2.2. Cell Culture for Assays 
The HUC-PC cell line was derived in the Department of 
Human Oncology, University of Wisconsin Medical School, 
and gifted by Dr. Rao from the University of California, 
Los Angeles. The cell line was cultured in F12 Ham en- 
riched Dulbecco’s Modified Eagle’s Meium (F12/DMEM 
purchased from Sigma, St. Louis, MO) with 1% penicil- 
lin (10,000 μg/ml) and streptomycin (10,000 mg/ml) and 
10% Fetal Bovine Serum (GIBCO BRL Isaland, New 
York, USA). Logarithmically growing HUC-PC cells 
were harvested and seeded in 96-well flat-bottle tissue 
culture plate (Greiner bio-one, Germany) at a concen- 
tration of 5 × 104 cells per microtitre well for cytotox- 
icity, FN and GAGs measurement. In parallel experi- 
ments, 1 × 106 cells were also seeded in 100-mm tissue 
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culture dishes (Greiner bio-one, Germany) for IL-6 as- 
say. 
2.3. Lactate Dehydrogenase (LDH) Cytotoxicity  
Assay  
Cytotoxicity of GLe and BCG was assayed by measuring 
LDH released from cells with LDH Cytotoxicity Detec- 
tion kit (TaKaRa Bio Inc., Shiga, Japan). Following the 
manufacturer’s instructions, the cells were incubated 
with assay media containing GLe or BCG for 24 hours in 
microtitre plate wells (Thermo Labsystems, Franklin, 
MA). No significant cytotoxicity was observed with the 
solvent controls. The release of LDH from cells was 
measured at 490 nm with reference wavelength at 690 
nm, using TECAN SPECTRA Fluor Plus microplate rea- 
der (TECAN Austria GmbH, Grodig, Austria). Untreat- 
ed cells were used as low controls to measure the spon- 
taneous LDH release, and Triton X-100 treated cells 
were used as high controls to measure the maximum re- 
leasable LDH activity. No interference was observed from 
any test substances used in the assay. Cytotoxicity was 
calculated as a percentage of LDH release with the fol- 
lowing formula: 
    
   490 490490 490
A Experiment A Low control
Cytotoxicity
A High control A Low control
100
 

 
2.4. Enzyme-Linked Immunosorbent Assay  
(ELISA) for IL-6 Cytokine 
Cultured supernatants were collected to measure the IL-6 
secretion with the Endogen® Human IL-6 ELISA kit 
(Pierce Biotechnology Inc, Rockford, USA). The ma- 
nufacturer’s instructions were followed. Culture me- 
dium was used to prepare the standard curve by serial 
dilutions (ranging from 0 pg/ml to 400 pg/ml). Ab- 
sorbance of the reaction microplate wells was meas- 
ured at 450 nm on microplate reader (TECAN, Aus- 
tria). 
2.5. Enzyme Immunoassay (EIA) for Fibronectin  
Quantitation  
Conditioned media were harvested from cell-seeded mic- 
rotitre plate after four hours (for avoiding cytotoxic ef- 
fects based on previous findings of apoptosis) of treat- 
ment with GLe. The TaKaRa Fibronectin EIA kit (TA- 
KARA Bio Inc., Japan) was used for assay. Following 
the kit instructions, a 100 μl of sample/standard was 
added into an ELISA well coated with human 
anti-fibronectin and incubated for one hour at 37˚C. The 
microtitre wells were washed four times and then 100 μl 
of substrate solution was added and incubated for 15 
minutes at room temperature. 1 N Sulphuric acid (H2SO4) 
was added to stop the reaction. Finally, absorbance was 
read against diluent blank at 450 nm, using TECAN 
SPECTRA Fluor Plus microplate reader (TECAN, Aus-
tria). 
2.6. Dimethylmethylene Blue (DMMB) Method  
for GAGs Quantitation  
After four hours of incubation, same as for FN assay, 
membrane-bound GAGs from HUC-PC cells were ex- 
tracted by a 0.1 M sodium acetate buffer at pH 5.8 in a 
microtitre plate overnight, in accordance with previous 
publication [28] with minor modifications. The super- 
natant was collected and digested overnight with 20 μl of 
papain (Merck, UK) at 65˚C. The isolated GAGs were 
assayed by the DMMB method [29]. A 50 μl of sam- 
ple/standard was added into each well of a new microtitre 
plate, which was followed by an addition of 200 μl of 
working DMMB (Aldrich, USA) reagent. Absorbance of 
the microtitre wells was read immediately against mil- 
liQ blank at 620 nm. GAGs solution (mixture of hyalu- 
ronate, chondroitin, sulphate, Keratan sulphate and he- 
paran sulphate) at 0, 4, 8, 16, and 32 μg/ml concentra- 
tions was used as standards. 
2.7. Statistical Analysis 
Each study group was run in triplicate and duplicated 
samples from each group were measured for each vari- 
able. Differences between means were determined using 
Student’s t-test (GraphPad Prism version 3.0 for Win- 
dows, San Diego California, USA). Statistical signifi- 
cance was sought at two tailed P-value of 0.05. 
3. Results 
3.1. Cytotoxicity and IL-6 Secretion Induced by  
GLe and BCG 
Results indicated that both BCG and GLe were clearly 
capable of inducing dose-dependent IL-6 secretion in 
the HUC-PC culture (Figure 1). GLe was shown to be 
cytotoxic to the HUC-PC cells. No LPS was detected 
in the β-D-glucan-inhibited fractions of GLe, while 
approximately 0.4 EU/ml of LPS was detected in BCG 
at 1.2 × 107 CFU. By serial dilution, 100% ± 12% 
(Mean ± SEM) of the cells was killed by 250 μg/ml of 
GLe, and the cytotoxic effects reached a plateau of 
100% at concentrations ranged 250 - 1000 μg/ml 
(Figure 2(a)). LD50 for GLe is between 180 - 190 
μg/ml for GLe, the dose-dependence was confirmed by 
repeating LDH cytotoxicity assay with GLe concen- 
trations at 40, 80, 100 and 200 μg/ml. Results indi- 
cated that 100% ± 5% and 13.8% ± 2% (Mean ± SEM) 
of cells were killed, by 200 μg/ml and 100 μg/ml of 
GLe respectively, but no cytotoxicity was found at 80 
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(a) 
 
(b) 
Figure 1. Dose-dependent IL-6 secretion was induced by BCG (a) and GLe (b). Culture media were harvested and measured 
at 24 hours after incubating with BCG at concentrations between 0.6 - 4.8 × 107 CFU while with GLe between 40 - 100 μg/ml 
(n = 3, error bar: SEM, **P < 0.01; ***P < 0.001). 
 
μg/ml or lower GLe concentration (Figure 2(b)). How- 
ever, after the 24 hours exposure, no significant cytotox- 
icity was observed by BCG up to dosage at 4.8 × 107 
CFU (Figure 2(a)). 
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(a) 
 
(b) 
Figure 2. Cytotoxicties of BCG and G. lucidum on HUC-PC cells measured by LDH cytotoxicity assay after 24-hour incuba- 
tion. (a) Serial dilution of GLe and BCG (starting concentrations of 1000 μg/ml and 4.8 × 107 CFU) were incubated with the 
cells. LD50 (→) was determined as 150 μg/ml for GLe (n = 3, error bar: SEM); (b) Dose-dependent cytotoxic effects of GLe at 
concentrations 40, 80, 100 and 200 μg/ml (n = 3, error bar: SEM). No cytotoxicity was detected at 40 and 80 μg/ml of GLe (*P 
< 0.05; ***P < 0.001). 
 
3.2. The Modulation of Extracellular FN and  
Cell-Surface GAGs by GLe 
About 15% of the free FN in the cultured media was sig- 
nificantly (P < 0.01) reduced by GLe at concentrations of 
40 - 100 μg/ml (Figure 3(a)). Such reduction may not be 
the maximum effects of GLe, as it was measured at 4 
hours after incubation to avoid the cytotoxic artefact. On  
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(b) 
Figure 3. Culture media were harvested and measured at 4 
hours after incubating with GLe (40, 80 and 100 μg/ml), 
which indicated the GLe-mediated reduction of extracellu- 
lar FN (n = 3, error bar: SEM, ***P < 0.001; **P < 0.01). 
Whilst cultured cells were harvested at the same time and 
treated for measurement, which indicated the elevat of cell 
surface GAGs (n = 3, error bar: SEM, ***P < 0.001; **P < 
0.01). 
 
the other hand, the cell-membrane bound GAGs levels on 
HUC-PC cells were significantly (P < 0.01) increased (Fig- 
ure 3(b)). 
4. Discussion 
In accordance with one of our recent publications [4], 
GLe has shown to be capable of stimulating IL-6 produc- 
tion in the HUC-PC cells. Current results indicated that 
the IL-6 secretions induced by GLe at 100 μg/ml and 
BCG at 4.8 × 107 CFU were almost quantitatively equi- 
valent. This is consistent with reports on the HPV-im- 
mortalized Hu35E6E7 HUC cell line [21] and other blad- 
der cancer cells [11,13-16] that IL-6 was commonly 
up-regulated by BCG. Lipopolysaccharide (LPS), a po- 
tent immune-stimulator is found in gram-negative bacte- 
ria but also easily being extracted from GL by ethanol 
[30,31]. However, results of LAL test indicated that 
unlike the BCG, GLe used in current study was negative 
for LPS. Thus, the BCG-mediated IL-6 secretion was at 
least partly owned to its LPS activities while the IL-6 
induced by GLe was not. At molecular level, the expres- 
sion of IL-6 mRNA in the Hu35E6E7 HUC cells was 
found to be exclusively triggered by BCG through the 
toll-like receptor (TLR) signaling [21]. NF-κB and AP-1 
are the main signaling pathways responsible for IL-6 
expression immediately upon BCG stimulation [32]. Co- 
herently, we have reported that GLe also enhanced the 
p50/p65 NF-κB activity during the immunological events 
in the HUC-PC cells [4]. In response to BCG, the NF- 
κB-mediated pathways and thus the IL-6 promoter con- 
structs were triggered through the cross-linking of α5β1 
integrin on the surface of human TCC cells and that able 
to induce cell cycle arrest [26,33]. The idea of “IL-6- 
activated tumor inhibition” has been proposed earlier 
[34]. IL-6 of autocrine and recombinant natures were 
demonstrated to be antiproliferative in TCC cell lines [26, 
35-37]. The inhibition of leukaemia cells mediated by 
GL was also once suggested to be responsible by the 
increased IL-6 secretion [38,39]. However, the concep-
tual role of cytotoxic IL-6 is arguable with the fact that 
normal and low-grade bladder cancer cells which have 
high capacity of internalizing BCG to induce IL-6 are 
less efficient being killed by BCG [16]. Cytotoxicity of 
BCG was shown to be more potent on poorly-differenti- 
ated highgrade bladder cancer cells than the low-grade 
ones [27]. This is further confirmed by the present results 
where BCG was shown to be non-cytotoxic to the HUC- 
PC cells, at least after 24-hour incubation that IL-6 was 
significantly induced. In contrast, cytotoxic effects of 
GLe and IL-6 induction were explicitly demonstrated at 
24 hours. Therefore, IL-6 is important to be an inductive 
marker for BCG internalization rather than its cytotoxic- 
ity in BCG-mediated prophylaxis in bladder cancer. 
The α5β1 integrin is a classic cellular receptor pres- 
ented on the malignant urothelium for fibronectin (FN) 
[26,33]. Expression of α5 and β1 mRNA could be pro- 
moted by exogenous and autocrine IL-6, while compe- 
tive inhibitors of FN inhibit BCG-induced NF-κB sig- 
naling pathways [33,40]. Furthermore, autocrine IL-6 en- 
hanced BCG adherence to the 253J TCC cell line through 
the up-regulation of α5β1 integrin receptor for FN [40]. 
In the present study, the up-regulation of IL-6 secretion 
in response to BCG suggested the HUC-PC cells are ca- 
pable of internalizing BCG, despite further elucidation is 
needed. FN is an essential adhesion glycoprotein for 
BCG binding to the surface of urothelium, internalization 
and production IL-6 [17,41,42]. There are two forms of FN: 
soluble and surface-bound [43]. Loss of cell surface FN 
on transformed cells is correlated with acquisition of 
tumorigenicity [44] and metastatic potential [45]. Such 
FN losses are mainly due to reduced synthesis, reduced 
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binding and increased degradation rate, and increased FN 
release into the extracellular matrix [43]. These FN mo- 
lecules facilitate cell-substrate adhesion, and thus en- 
hance the interaction between the urothelium and ex- 
tracellular matrix, and ultimately affect the cell mor- 
phology, cytoskeletal organization, migration and differ- 
entiation [46]. About 90% of urothelial tumor stroma was 
positive for FN immunohistochemical expression [47]. 
Expression of extracellular FN is correlated with tumor 
progression for invasiveness and aggressiveness [47,48]. 
Blocking of FN attachment sites on TCC cells inhibits 
the tumor outgrowth in vivo [49]. The diagnostic roles of 
soluble FN in urine have been proposed and its elevated 
levels are associated with tumor stage, degree of differen- 
tiation, tumor size, multifocal nature or macroscopic ap- 
pearance [46,50]. Clinical data supported that persistent 
elevation of urinary FN causes BCG failure after com- 
plete TUR [51]. Excess soluble FN, whether from exoge- 
nous or autocrine origin, also saturates mycobacterial and 
cell surface FN receptors simultaneously, and precludes the 
bridging ability of a single FN molecule, impairing α5β1 
integrin/integrin mediated NF-κB signal transduction which 
is considered to be critical for BCG prophylaxis [22]. Thus, 
free FN in the culture media is regarded as a key factor 
for both carcinogenesis of urothelial cells and BCG binding. 
In contrast, cell surface expression of FN is comparatively 
less important regarding its roles in bladder chemopreven- 
tion. Current findings indicated that free FN was reduced in 
the culture media of treated HUC-PC cells by GLe. 
Furthermore, the expression of GAGs on the HUC-PC 
cell surface was also increased by GLe. Formerly known 
as mucopolysaccharides, GAGs are long unbranched po- 
lysaccharides, are highly anionic and are often bound to 
core proteins to become proteoglycans with varying pro- 
perties of extracellular matrices of tissues [52,53]. GAGs 
are extremely hydrophilic and trap water at the outer 
layer of the umbrella urothelium, and this trapped water 
forms a gel as part of the mucosal barrier that interfaces 
urine and the bladder wall [54,55]. This provides a pro- 
tective barrier that becomes highly impermable to any 
solutes, crystals and even bacteria in urine [54,56]. The 
disruption of this mucosal permeability is pathologically 
significant such that interstitial cystitis (IC) occurs [54, 
57]. GAGs are also able to repair damaged bladder mu- 
cosa [54]. In addition, anti-adherence properties of GAGs 
have primary innate defence against bacterial attacks [52, 
54,56]. Experimental removal of GAGs from the urothe-
lial surface causes a ten-fold higher bacterial adherence 
[58]. Therefore, the effects of GLe on cell-surface GAGs 
may strengthen the mucosal barrier of the urothelium, 
repair the urothelial damage induced by BCG therapy, as 
well as prevent the side effects of BCG therapy, such as 
cystitis and infections. 
In summary, ethanol extract of GL exerted as a similar 
activator for IL-6 production as BCG in the HUC-PC 
cells. IL-6 was the only cytokine selected for measure- 
ment because it is the earliest cytokine that can be de- 
tected after BCG exposure to urothelial cells and it is 
also an indicator for successful BCG internalization by 
these cells. Current results suggested that combinational 
use of GLe and BCG may exert synergistic effects in sev-
eral ways (Figure 4): Firstly, the cytotoxic and cytokine 
secretion can be additive to BCG activities; Secondly, the 
reduction of free FN can facilitate BCG binding to the  
 
 
Figure 4. A summary of GLe effects on the HUC-PC cells to deduce the potential synergism between BCG and GLe. 
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urothelial surface for subsequent internalization and IL-6 
secretion, particularly for cells at normal or low grades. 
Nonetheless, the reduction of free FN, by itself may also 
suggest being tumor suppressive to inhibit the growth 
and progression by reducing unnecessary cell-substrate 
interactions; and thirdly, the increased cell surface GAGs 
expression provide additional protection from chemical 
and bacterial attacks, and thus is potential in reducing 
side-effects caused by BCG. Further experiments are 
underway to define the synergism of GLe and BCG as 
well as to investigate the underlying mechanisms. No 
doubt, the anticancer activities of GLe were demon- 
strated in the HUC-PC cell model to suggest the associa- 
tions between IL-6 induction, FN reduction, and BCG- 
GLe synergism were suggested. However, the cause-and- 
effect mechanism needs to be confirmed by further care- 
ful scientific investigation. 
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